02:33 , Dec 8, 2018 |  BioCentury  |  Product Development

Intermittent move beyond Blincyto

A swath of data at ASH shows that companies have been able to move beyond the 28-day continuous dosing of Amgen Inc.’s first-generation BiTE, Blincyto, to build next-generation antibodies with more convenient, intermittent dosing and...
03:50 , Dec 1, 2018 |  BioCentury  |  Product Development

Cell therapy momentum at ASH

This year’s American Society of Hematology (ASH) meeting will showcase a surge in clinical CAR T cell presentations. But gene therapies are not following the same trajectory, despite both modalities being fresh off their first...
23:56 , Jul 26, 2018 |  BC Extra  |  Company News

Reese succeeding Harper as Amgen EVP of R&D

Amgen Inc. (NASDAQ:AMGN) said EVP of R&D Sean Harper will retire and be succeeded by SVP of Translational Sciences and Oncology David Reese. The company also reported 2Q18 earnings on Thursday after market hours that...
19:52 , Jul 28, 2017 |  BC Week In Review  |  Company News

Amgen gets rights to Captisol formulation technology for BiTE AMG 330

Ligand Pharmaceuticals Inc. (NASDAQ:LGND) granted Amgen Inc. (NASDAQ:AMGN) exclusive, worldwide commercialization rights to combine Captisol formulation technology with AMG 330 to treat multiple indications. Ligand received an undisclosed upfront payment and is eligible for milestones...
01:38 , Sep 17, 2015 |  BC Extra  |  Company News

Amgen, Xencor partner on bispecific antibodies

Amgen Inc. (NASDAQ:AMGN) and Xencor Inc. (NASDAQ:XNCR) partnered to develop six preclinical programs in cancer and inflammation using Xencor's XmAb bispecific antibody platform. Xencor President and CEO Bassil Dahiyat told BioCentury that Xencor will use...